The c-abl gene encodes a protein tyrosine kinase and is transcribed from at least two promoters giving rise to transcripts of two size classes of approximately 5 and 6 kb in length. These mRNAs only differ in their most 5' exon and encode proteins of similar size but with different N-termini. In the mouse testis an additional abundant c-abl mRNA of 4 kb is detected. This mRNA was shown to be expressed in the haploid male germ cells of the adult mouse. Here we describe the cloning and molecular characterization of a cDNA representing the testis specific c-abl transcript. We show that the 4 kb c-abl mRNA arises from alternative polyadenylation of an RNA transcribed from the same promoter as the 5 kb mRNA. The site of polyadenylation is unusual in this shorter transcript as it is not preceded by the highly conserved hexanucleotide AAUAAA. The use of this polyadenylation site removes 1.2 kb of 3' sequences present in the somatic c-abl mRNAs, but does not affect the main open reading frame of the transcript. Using in situ hybridization on whole testis sections it is shown that the 4 kb c-abl mRNA is most abundant in the elongating spermatids.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC553886PMC
http://dx.doi.org/10.1002/j.1460-2075.1987.tb02749.xDOI Listing

Publication Analysis

Top Keywords

c-abl mrna
16
molecular characterization
8
testis specific
8
specific c-abl
8
c-abl
7
mrna
6
testis
4
characterization testis
4
mrna mouse
4
mouse c-abl
4

Similar Publications

New biological markers in diagnosis and follow-up of brucellosis cases.

Diagn Microbiol Infect Dis

February 2025

Department of Immunology, Bursa Uludag University Faculty of Medicine, Bursa, Turkey. Electronic address:

Brucellosis remains a significant public health issue in some parts of the world. It is clear that new laboratory methods are needed to diagnose brucellosis. Currently, no test method meets the criteria of high specificity, sensitivity, reliability, and low cost for the diagnosis of brucellosis, which could also predict chronicity.

View Article and Find Full Text PDF
Article Synopsis
  • - Nilotinib is an FDA-approved drug for chronic myeloid leukemia that may have potential neuroprotective effects, leading researchers to investigate its use in treating Alzheimer's disease (AD) and Parkinson's disease (PD).
  • - The study examined nilotinib's impact on amyloid processing and mitochondrial function in SH-SY5Y neuroblastoma cells, finding no significant changes in key gene expressions related to amyloid-β processing or neuronal health.
  • - While BACE1 and ADAM10 proteins were increased at certain nilotinib concentrations, overall results suggest that nilotinib does not effectively provide neuroprotection.
View Article and Find Full Text PDF

Platelets are essential blood components that maintain hemostasis, prevent excessive bleeding, and facilitate wound healing. Reduced platelet counts are implicated in various diseases, including leukemia, hepatitis, cancer, and Alzheimer's disease. Enhancing megakaryocytic differentiation is a promising strategy to increase platelet production.

View Article and Find Full Text PDF

[Effect and molecular mechanism of hesperadin-induced ferroptosis in chronic myeloid leukemia K562 cells].

Zhonghua Xue Ye Xue Za Zhi

June 2024

Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, Taiyuan 030001, China.

To investigate the effect and molecular mechanism of hesperadin in inducing ferroptosis in chronic myeloid leukemia cell line K562 cells. The effects of hesperadin on the viability, proliferation, and migration of K562 cells were detected though CCK8, EDU-594, and Transwell assays, and the apoptotic rate of K562 cells was detected by flow cytometry. In addition, C11-BODIPY and FerroOrange were utilized to detect intracellular lipid peroxidation and Fe(2+) levels.

View Article and Find Full Text PDF

Chronic myeloid leukemia (CML), caused by BCR::ABL1 fusion gene, is known to regulate disease progression by altering the expression of genes. However, the molecular mechanisms underlying these changes are largely unknown. In this study, we identified RNA Exonuclease 5 (REXO5/LOC81691) as a novel gene with elevated mRNA expression levels in chronic myeloid leukemia (CML) patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!